HCW Biologics Inc is trading 3.5% up today at $2.05 after disclosing that Nasdaq granted the company an extension to regain minimum bid-price compliance, significantly reducing near-term delisting risks.
- The extension provides the company with additional time to meet the exchange's $1.00 minimum bid price requirement.
- Positive sentiment is further supported by a recent Q1 2026 earnings report that delivered a substantial EPS surprise versus consensus estimates.
- Investors appear optimistic regarding the company's fundamental trajectory despite the current lack of product revenue.